| Q59813731 | A pilot study to evaluate the effects of vardenafil on sexual distress in men with obesity |
| Q34286787 | An Update of the International Society of Sexual Medicine's Guidelines for the Diagnosis and Treatment of Premature Ejaculation (PE). |
| Q34286782 | An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second international society for sexual medicine ad hoc committee for the definition of premature ejaculation |
| Q40715367 | Assessing satisfaction in men with premature ejaculation after dapoxetine treatment in real-world practice |
| Q89998658 | Clinical correlation between erectile function and ejaculatory function in the Czech male population |
| Q40349228 | Clomiphene Effects on Idiopathic Premature Ejaculation |
| Q48154104 | Comparison of the clinical efficacy and safety of the on-demand use of paroxetine, dapoxetine, sildenafil and combined dapoxetine with sildenafil in treatment of patients with premature ejaculation: A randomised placebo-controlled clinical trial |
| Q35852000 | Correlation between lower urinary tract symptoms and premature ejaculation in Korean men older than 40 years old [corrected] |
| Q37085368 | Current therapeutic strategies for premature ejaculation and future perspectives |
| Q38713732 | Dapoxetine and the treatment of premature ejaculation |
| Q33692658 | Effect of tadalafil 5mg daily treatment on the ejaculatory times, lower urinary tract symptoms and erectile function in patients with erectile dysfunction |
| Q92381259 | Effectiveness and tolerability of lidocaine 5% spray in the treatment of lifelong premature ejaculation patients: a randomized single-blind placebo-controlled clinical trial |
| Q53116980 | Effects of 12 weeks of tadalafil treatment on ejaculatory and orgasmic dysfunction and sexual satisfaction in patients with mild to severe erectile dysfunction: integrated analysis of 17 placebo-controlled studies. |
| Q38908136 | Efficacy and safety of dapoxetine in treatment of premature ejaculation: an evidence-based review |
| Q28071637 | Ejaculatory dysfunction-the evolution of a new understanding |
| Q28066358 | Epidemiology of delayed ejaculation |
| Q63386748 | Evidence for a genetic etiology to ejaculatory dysfunction |
| Q45052984 | Factors associated with ejaculatory and orgasmic dysfunction in men with erectile dysfunction: analysis of clinical trials involving the phosphodiesterase type 5 inhibitor tadalafil |
| Q38304841 | Hormonal correlations of premature ejaculation |
| Q58640962 | How the Prevalence Rates of Male Sexual Dysfunction Vary Using Different Criteria |
| Q46359302 | Increased prevalence of premature ejaculation in men with metabolic syndrome |
| Q91838400 | Interventions to Treat Erectile Dysfunction and Premature Ejaculation: An Overview of Systematic Reviews |
| Q36305415 | Inventories for male and female sexual dysfunctions |
| Q37832643 | Is there a role for phosphodiesterase type-5 inhibitors in the treatment of premature ejaculation? |
| Q89746239 | Lifestyles and sexuality in men and women: the gender perspective in sexual medicine |
| Q35425021 | Medical therapy for premature ejaculation |
| Q34306031 | New insights on premature ejaculation: a review of definition, classification, prevalence and treatment |
| Q48505554 | Penile sensory thresholds in subtypes of premature ejaculation: implications of comorbid erectile dysfunction. |
| Q35136178 | Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers. |
| Q36435863 | Phosphodiesterase 5 inhibitors in the treatment of premature ejaculation |
| Q88871917 | Premature Ejaculation Among Italian Men: Prevalence and Clinical Correlates From an Observational, Non-Interventional, Cross-Sectional, Epidemiological Study (IPER) |
| Q36814690 | Premature ejaculation in type II diabetes mellitus patients: association with glycemic control. |
| Q47139929 | Premature ejaculation: challenging new and the old concepts. |
| Q34286614 | Psychometric properties of the Iranian version of the premature ejaculation diagnostic tool. |
| Q26746754 | Psychosexual disorders and dermatologists |
| Q44597942 | Psychosocial factors associated with male sexual difficulties. |
| Q39476922 | Relation of size of seminal vesicles on ultrasound to premature ejaculation |
| Q90196237 | The Comorbidity Between Premature Ejaculation and Erectile Dysfunction-A Cross-Sectional Internet Survey |
| Q92506939 | The Sentiment Analysis of Tweets as a New Tool to Measure Public Perception of Male Erectile and Ejaculatory Dysfunctions |
| Q28071375 | The design and methodology of premature ejaculation interventional studies |
| Q51367994 | The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study. |
| Q47427809 | The impact of premature ejaculation on the subjective perception of orgasmic intensity: validation and standardisation of the 'Orgasmometer'. |
| Q28066740 | The office management of ejaculatory disorders |
| Q28066668 | The pathophysiology of acquired premature ejaculation |
| Q28074664 | The pathophysiology of lifelong premature ejaculation |
| Q48699591 | The relationship between acquired premature ejaculation and metabolic syndrome: a prospective, comparative study |
| Q50925312 | Thyroid hormones and male sexual function. |
| Q47165621 | Validity of premature ejaculation diagnostic tool and its association with International Index of Erectile Function-15 in Chinese men with evidence-based-defined premature ejaculation |